DK2318519T3 - PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS - Google Patents
PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS Download PDFInfo
- Publication number
- DK2318519T3 DK2318519T3 DK09807366.1T DK09807366T DK2318519T3 DK 2318519 T3 DK2318519 T3 DK 2318519T3 DK 09807366 T DK09807366 T DK 09807366T DK 2318519 T3 DK2318519 T3 DK 2318519T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- mesenchymal stem
- mscs
- paragraph
- less
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 320
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 124
- 210000004027 cell Anatomy 0.000 claims description 80
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 58
- 229940098773 bovine serum albumin Drugs 0.000 claims description 56
- 230000035899 viability Effects 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 220
- 238000000034 method Methods 0.000 description 104
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 81
- 238000005516 engineering process Methods 0.000 description 71
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 62
- 238000000746 purification Methods 0.000 description 59
- 239000008194 pharmaceutical composition Substances 0.000 description 50
- 239000006285 cell suspension Substances 0.000 description 48
- 239000012588 trypsin Substances 0.000 description 46
- 102000004142 Trypsin Human genes 0.000 description 43
- 108090000631 Trypsin Proteins 0.000 description 43
- 108090000144 Human Proteins Proteins 0.000 description 38
- 102000003839 Human Proteins Human genes 0.000 description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 210000002966 serum Anatomy 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- 239000000126 substance Substances 0.000 description 27
- 238000001914 filtration Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 239000000725 suspension Substances 0.000 description 23
- 230000008569 process Effects 0.000 description 22
- 201000010099 disease Diseases 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 206010020751 Hypersensitivity Diseases 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 238000005119 centrifugation Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 208000026935 allergic disease Diseases 0.000 description 14
- 230000007815 allergy Effects 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000002753 trypsin inhibitor Substances 0.000 description 14
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000009987 spinning Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000002659 cell therapy Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 101710081722 Antitrypsin Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 101710162629 Trypsin inhibitor Proteins 0.000 description 7
- 229940122618 Trypsin inhibitor Drugs 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000001475 anti-trypsic effect Effects 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 5
- 235000021120 animal protein Nutrition 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000012888 bovine serum Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000008151 electrolyte solution Substances 0.000 description 5
- 229940021013 electrolyte solution Drugs 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012595 freezing medium Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 206010040400 serum sickness Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010051841 Exposure to allergen Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 230000035495 ADMET Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010535 acyclic diene metathesis reaction Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000013009 nonpyrogenic isotonic solution Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8889808P | 2008-08-14 | 2008-08-14 | |
| PCT/US2009/053891 WO2010019886A1 (en) | 2008-08-14 | 2009-08-14 | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2318519T3 true DK2318519T3 (en) | 2017-01-16 |
Family
ID=41669330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09807366.1T DK2318519T3 (en) | 2008-08-14 | 2009-08-14 | PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8637004B2 (enExample) |
| EP (3) | EP2318519B1 (enExample) |
| JP (7) | JP6025329B2 (enExample) |
| AR (2) | AR073069A1 (enExample) |
| AU (1) | AU2009281809B2 (enExample) |
| BR (1) | BRPI0917993B8 (enExample) |
| CA (1) | CA2733985C (enExample) |
| DK (1) | DK2318519T3 (enExample) |
| ES (1) | ES2608974T3 (enExample) |
| IL (1) | IL211214A0 (enExample) |
| MX (2) | MX362512B (enExample) |
| NZ (2) | NZ591146A (enExample) |
| WO (1) | WO2010019886A1 (enExample) |
| ZA (1) | ZA201101858B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2564679C (en) | 2004-03-22 | 2015-06-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
| WO2007087139A2 (en) | 2006-01-13 | 2007-08-02 | Osiris Therapeutics, Inc. | MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR |
| CA2733985C (en) | 2008-08-14 | 2016-07-12 | Osiris Therapeutics, Inc. | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions |
| EP3539380A3 (en) | 2008-08-20 | 2019-12-18 | Celularity, Inc. | Improved cell composition and methods of making the same |
| US9192695B2 (en) | 2008-11-20 | 2015-11-24 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
| US20140286911A1 (en) | 2013-03-15 | 2014-09-25 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
| WO2012048093A2 (en) | 2010-10-08 | 2012-04-12 | Osiris Therapeutics, Inc. | Enhanced msc preparations |
| EP2625263B1 (en) | 2010-10-08 | 2020-03-11 | Terumo BCT, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| ITGE20120034A1 (it) * | 2012-03-28 | 2013-09-29 | Carlo Tremolada | Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali |
| JP2013252126A (ja) * | 2012-05-08 | 2013-12-19 | Otsuka Pharmaceut Factory Inc | デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
| WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US10449283B2 (en) * | 2016-04-29 | 2019-10-22 | Fenwal, Inc. | System and method for selecting and culturing cells |
| US10251990B2 (en) | 2016-04-29 | 2019-04-09 | Fenwal, Inc. | System and method for processing, incubating, and/or selecting biological cells |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| EP3338823B1 (en) | 2016-12-21 | 2021-06-16 | Fenwal, Inc. | System and method for separating cells incorporating magnetic separation |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| JP7393945B2 (ja) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | 細胞増殖 |
| KR20200088445A (ko) | 2017-11-22 | 2020-07-22 | 메조블라스트 인터내셔널 에스에이알엘 | 세포 조성물 및 치료 방법 i |
| WO2019204646A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| WO2020084135A1 (en) * | 2018-10-26 | 2020-04-30 | Stemselect | Method and apparatus for mesenchymal stem cells isolation and purification |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| CA3137570A1 (en) * | 2019-05-15 | 2020-11-19 | Stemcyte Inc. | High concentration cell packaging and shipping |
| WO2021144995A1 (ja) * | 2020-01-16 | 2021-07-22 | ＰｕＲＥＣ株式会社 | 高純度間葉系幹細胞 |
| EP4146787A4 (en) | 2020-05-08 | 2024-06-26 | Gallant Pet, Inc. | Uterine-derived regenerative cell compositions and uses thereof |
| US12043823B2 (en) | 2021-03-23 | 2024-07-23 | Terumo Bct, Inc. | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| CN115478046A (zh) * | 2022-09-30 | 2022-12-16 | 浙江泉生生物科技有限公司 | 一种降低血清培养体系中细胞制剂bsa残留量的方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034135A (en) | 1982-12-13 | 1991-07-23 | William F. McLaughlin | Blood fractionation system and method |
| US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
| JP2881305B2 (ja) * | 1986-08-11 | 1999-04-12 | バクスター、インターナショナル、インコーポレイテッド | 血球洗浄システムおよび方法 |
| US5536475A (en) * | 1988-10-11 | 1996-07-16 | Baxter International Inc. | Apparatus for magnetic cell separation |
| US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
| US5234608A (en) * | 1990-12-11 | 1993-08-10 | Baxter International Inc. | Systems and methods for processing cellular rich suspensions |
| JPH10505250A (ja) * | 1994-06-06 | 1998-05-26 | ケース ウエスターン リザーブ ユニバーシティ | 組織再生のためのバイオマトリックス |
| US5707996A (en) * | 1995-11-06 | 1998-01-13 | Macleod Pharmaceuticals, Inc. | Pharmaceutical solution and methods for preparation thereof |
| AU731468B2 (en) * | 1996-04-19 | 2001-03-29 | Mesoblast International Sarl | Regeneration and augmentation of bone using mesenchymal stem cells |
| US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| DK1007631T4 (da) * | 1997-07-14 | 2009-04-27 | Osiris Therapeutics Inc | Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| JP4740452B2 (ja) | 1998-03-18 | 2011-08-03 | オシリス セラピューティクス，インコーポレイテッド | 移植で免疫応答の予防と処置のための間葉幹細胞を利用する方法、組成物およびその使用法 |
| CA2328425A1 (en) * | 1998-05-22 | 1999-12-02 | Osiris Therapeutics, Inc. | Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells |
| FR2787463B1 (fr) | 1998-12-21 | 2001-03-30 | Neurotech | Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant |
| JP2002325572A (ja) * | 2000-12-25 | 2002-11-12 | Univ Osaka | 外来物質の導入方法 |
| US20030054331A1 (en) * | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
| US7514075B2 (en) * | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
| US8404229B2 (en) * | 2001-12-07 | 2013-03-26 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to treat acute tubular necrosis |
| US8105580B2 (en) * | 2001-12-07 | 2012-01-31 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to promote wound healing |
| US20050008626A1 (en) | 2001-12-07 | 2005-01-13 | Fraser John K. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| US9597395B2 (en) * | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| EP2308963A3 (en) * | 2001-12-07 | 2011-09-21 | Cytori Therapeutics, Inc. | System for processing lipoaspirate cells |
| US20050048036A1 (en) * | 2001-12-07 | 2005-03-03 | Hedrick Marc H. | Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues |
| US7585670B2 (en) * | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
| US20050095228A1 (en) * | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| ITTO20020311A1 (it) * | 2002-04-10 | 2003-10-10 | Medestea Int Spa | Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t |
| ZA200404101B (en) | 2003-05-26 | 2005-03-07 | Reliance Life Sciences Pvt Ltd | In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use. |
| AU2004260937B2 (en) | 2003-06-25 | 2010-05-13 | Macropore Biosurgery Inc. | Systems and methods for separating and concentrating regenerative cells from tissue |
| CA2564679C (en) * | 2004-03-22 | 2015-06-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
| JP3828905B2 (ja) * | 2004-08-05 | 2006-10-04 | 株式会社Ｒ＆Ｄセルサイエンス・オプショナルメディコ | 局所麻酔薬を含有する細胞凝集抑制剤 |
| WO2006135854A2 (en) * | 2005-06-10 | 2006-12-21 | Board Of Regents, The University Of Texas System | Antiseptic compositions |
| EP1996013A4 (en) | 2005-09-21 | 2010-03-10 | Dask Technologies Llc | METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES |
| US7888119B2 (en) * | 2005-10-14 | 2011-02-15 | University Of Central Florida Research Foundation, Inc. | Tissue substitutes comprising stem cells and reduced ceria |
| US20070253931A1 (en) * | 2006-01-12 | 2007-11-01 | Osiris Therapeutics, Inc. | Use of mesenchymal stem cells for treating genetic diseases and disorders |
| WO2007089798A2 (en) | 2006-01-30 | 2007-08-09 | University Of Virginia Patent Foundation | Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof |
| EP2021035B1 (en) | 2006-05-19 | 2020-08-05 | Versitech Limited | Cell-matrix microspheres, methods for preparation and applications |
| JP2010500047A (ja) | 2006-08-15 | 2010-01-07 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 間葉系幹細胞馴化培地 |
| CA2913024A1 (en) * | 2006-11-03 | 2008-05-08 | Aastrom Biosciences, Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
| JP2008139106A (ja) * | 2006-11-30 | 2008-06-19 | Sysmex Corp | 骨髄穿刺液収容具及び骨髄穿刺液濾過方法 |
| KR20090086260A (ko) | 2006-12-07 | 2009-08-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 미손상 골수 또는 미손상 제대 조직으로부터 조직 전구체 세포 및 성숙 조직 세포를 형성 및 증식시키는 방법 |
| CN101210232B (zh) * | 2006-12-28 | 2012-07-18 | 天津昂赛细胞基因工程有限公司 | 一种间充质干细胞保存液 |
| EP2191835A4 (en) | 2007-09-07 | 2011-12-14 | Japan Chem Res | THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS |
| JP5394932B2 (ja) | 2007-11-02 | 2014-01-22 | 日本ケミカルリサーチ株式会社 | ヒト間葉系幹細胞含有医薬組成物 |
| CA2733985C (en) | 2008-08-14 | 2016-07-12 | Osiris Therapeutics, Inc. | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions |
| US8048976B2 (en) | 2008-09-04 | 2011-11-01 | Amyris, Inc. | Polyfarnesenes |
| US10476476B2 (en) | 2016-12-15 | 2019-11-12 | Murata Manufacturing Co., Ltd. | MEMS resonator with suppressed spurious modes |
-
2009
- 2009-08-14 CA CA2733985A patent/CA2733985C/en active Active
- 2009-08-14 EP EP09807366.1A patent/EP2318519B1/en not_active Revoked
- 2009-08-14 EP EP24209880.4A patent/EP4477742A3/en active Pending
- 2009-08-14 WO PCT/US2009/053891 patent/WO2010019886A1/en not_active Ceased
- 2009-08-14 MX MX2014008542A patent/MX362512B/es unknown
- 2009-08-14 AU AU2009281809A patent/AU2009281809B2/en active Active
- 2009-08-14 JP JP2011523195A patent/JP6025329B2/ja active Active
- 2009-08-14 DK DK09807366.1T patent/DK2318519T3/en active
- 2009-08-14 NZ NZ591146A patent/NZ591146A/xx unknown
- 2009-08-14 US US12/541,282 patent/US8637004B2/en active Active
- 2009-08-14 MX MX2011001730A patent/MX2011001730A/es active IP Right Grant
- 2009-08-14 EP EP16189444.9A patent/EP3124601A1/en active Pending
- 2009-08-14 ES ES09807366.1T patent/ES2608974T3/es active Active
- 2009-08-14 BR BRPI0917993A patent/BRPI0917993B8/pt active IP Right Grant
- 2009-08-14 NZ NZ602248A patent/NZ602248A/en unknown
- 2009-08-18 AR ARP090103159A patent/AR073069A1/es not_active Application Discontinuation
-
2011
- 2011-02-14 IL IL211214A patent/IL211214A0/en active IP Right Grant
- 2011-03-10 ZA ZA2011/01858A patent/ZA201101858B/en unknown
-
2013
- 2013-12-16 US US14/107,031 patent/US20140105872A1/en not_active Abandoned
-
2014
- 2014-11-04 JP JP2014224180A patent/JP2015071610A/ja active Pending
-
2017
- 2017-01-04 JP JP2017000107A patent/JP2017081972A/ja active Pending
- 2017-05-23 US US15/602,848 patent/US20180008642A1/en not_active Abandoned
-
2018
- 2018-03-01 JP JP2018036415A patent/JP2018109052A/ja active Pending
-
2019
- 2019-11-25 US US16/694,382 patent/US20200197444A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020072934A patent/JP7580202B2/ja active Active
- 2020-05-05 AR ARP200101271A patent/AR123811A2/es not_active Application Discontinuation
-
2022
- 2022-09-23 US US17/934,852 patent/US20230089901A1/en not_active Abandoned
-
2023
- 2023-01-05 JP JP2023000381A patent/JP2023052211A/ja active Pending
-
2025
- 2025-03-20 US US19/086,003 patent/US20250312379A1/en active Pending
- 2025-05-23 JP JP2025086455A patent/JP2025122125A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250312379A1 (en) | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions | |
| JP4936341B2 (ja) | 細胞増殖方法ならびに組織の修復および再生のための医薬 | |
| KR102722188B1 (ko) | 씨디39 기질 줄기세포 단리 방법 및 용도 | |
| JP2019031566A (ja) | プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置 | |
| JP5598864B2 (ja) | 細胞増殖方法ならびに組織の修復および再生のための医薬 | |
| JP2021516052A (ja) | 胸腺組織に由来する制御性ｔ細胞を入手する方法および免疫系障害における細胞免疫療法としての前記細胞の使用 | |
| CN114901806A (zh) | 细胞群以及其取得方法 | |
| AU2015268673B2 (en) | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions | |
| HK1229851A (en) | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions | |
| HK1229851A1 (en) | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions | |
| HK40115560A (en) | Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions | |
| JP2024524520A (ja) | 動物の変形性関節症の治療で使用するための間葉系幹細胞 | |
| WO2023076279A1 (en) | Engineered tissue constructs for the treatment of crigler-najjar syndrome |